Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Replimune Group, Inc.REPL · Entity 4707 | Chief Operating Officer | May 16, 2024 | May 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Replimune Group, Inc.
Report date May 16, 2024 · Filed May 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 777,345 |
Reported balance
After 2024-05-16 transaction · row 1
1 source rowRow 1 · 2024-05-16 · Sale · Disposed 17,615 · Balance 777,345 F1: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person. F2: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $6.46 to $6.56 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person.
F2: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $6.46 to $6.56 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2024 Filed May 20, 2024 20:05 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 17,615 | $6.47 | $113,969.05 |
DisclosureSEC source: 0001104659-24-063562 · tm2414961-5_4seq1.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 777,345 F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $6.46 to $6.56 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:33 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 10,775 | $18.05 | $194,488.75 |
DisclosureSEC source: 0001104659-23-062375 · tm2316199-6_4seq1.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 794,960 F1 · shares: Represents shares of the Issuer's common stock sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreement under which the RSU was granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.05 to $18.25. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 20:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $17.66 | $0.00 |
DisclosureSEC source: 0001104659-23-041723 · tm2311410-5_4seq1.xml · derivative · entry 2 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2033-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2024, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 20:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-041723 · tm2311410-5_4seq1.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 805,735 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2024 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2027, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| May 16, 2022 Filed May 18, 2022 19:04 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 6,324 | $14.59 | $92,267.16 |
DisclosureSEC source: 0001104659-22-062611 · tm2215879-8_4seq1.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 765,735 F1 · shares: Represents shares of the Issuer's common stock sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreement under which the RSU was granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.58 to $14.59. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 16:14 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 39,375 | $0.00 Strike: $18.26 | $0.00 |
DisclosureSEC source: 0001104659-22-042760 · tm2211665-7_4seq1.xml · derivative · entry 2 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,375 Underlying: Common Stock · 39,375 shares Expires 2032-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2023, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 16:14 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042760 · tm2211665-7_4seq1.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 772,059 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2023 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2026, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| October 18, 2021 Filed Oct 19, 2021 21:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 12,711 | $29.58 | $375,991.38 |
DisclosureSEC source: 0001104659-21-127727 · tm2130435-1_4seq1.xml · nonDerivative · entry 3 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 745,809 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.32 to $29.96. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F5 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 745,809 shares of the Issuer's common stock. The reporting person also holds options to acquire 503,578 shares of the Issuer's common stock, 323,448 of which are exercisable as of the date hereof. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 21:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 15,089 | $30.31 | $457,347.59 |
DisclosureSEC source: 0001104659-21-127727 · tm2130435-1_4seq1.xml · nonDerivative · entry 2 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 758,520 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.97 to $30.69. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 21:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 2,200 | $31.16 | $68,552.00 |
DisclosureSEC source: 0001104659-21-127727 · tm2130435-1_4seq1.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 773,609 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.90 to $31.72. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 21:11 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 30,000 | $31.23 | $936,900.00 |
DisclosureSEC source: 0001104659-21-117070 · tm2127933-1_4seq1.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 775,809 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.86 to $31.77. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 775,809 shares of the Issuer's common stock. The reporting person also holds options to acquire 503,578 shares of the Issuer's common stock, 315,211 of which are exercisable as of the date hereof. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 21:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 2,700 | $29.27 | $79,029.00 |
DisclosureSEC source: 0001104659-21-107453 · tm2125440-1_4seq1.xml · nonDerivative · entry 2 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 805,809 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.05 to $29.39. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 805,809 shares of the Issuer's common stock. The reporting person also holds options to acquire 503,578 shares of the Issuer's common stock, 309,057 of which are exercisable as of the date hereof. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 21:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 27,300 | $30.00 | $819,000.00 |
DisclosureSEC source: 0001104659-21-107453 · tm2125440-1_4seq1.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 808,509 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.42 to $30.39. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 21:03 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 30,000 | $32.02 | $960,600.00 |
DisclosureSEC source: 0001104659-21-093195 · tm2122438-1_4seq1.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 835,809 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 835,809 shares of the Issuer's common stock. The reporting person also holds options to acquire 503,578 shares of the Issuer's common stock, 299,790 of which are exercisable as of the date hereof. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 21:47 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 12,200 | $34.53 | $421,266.00 |
DisclosureSEC source: 0001104659-21-082229 · tm2119957-1_4seq1.xml · nonDerivative · entry 2 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 865,809 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.29 to $34.75. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 865,809 shares of the Issuer's common stock. The reporting person also holds options to acquire 503,578 shares of the Issuer's common stock, 290,523 of which are exercisable as of the date hereof. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 21:47 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 17,800 | $33.80 | $601,640.00 |
DisclosureSEC source: 0001104659-21-082229 · tm2119957-1_4seq1.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 878,009 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.29 to $34.27. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 18:35 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 2,700 | $29.98 | $80,946.00 |
DisclosureSEC source: 0001104659-21-052071 · tm2113387-1_4seq1.xml · nonDerivative · entry 2 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 895,809 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.76 to $30.17. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 895,809 shares of the Issuer's common stock. The reporting person also holds options to acquire 503,578 shares of the Issuer's common stock, 274,077 of which are exercisable as of the date hereof. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 18:35 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 27,300 | $30.69 | $837,837.00 |
DisclosureSEC source: 0001104659-21-052071 · tm2113387-1_4seq1.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 898,509 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.22 to $31.19. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:17 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 58,925 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046727 · tm2112099-9_4seq1.xml · derivative · entry 2 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,925 Underlying: Common Stock · 58,925 shares Expires 2031-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2022, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:17 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 39,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-046727 · tm2112099-9_4seq1.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 925,809 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2022 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2025, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 21:07 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 100 | $32.67 | $3,267.00 |
DisclosureSEC source: 0001104659-21-037933 · tm219986-1_4seq1.xml · nonDerivative · entry 3 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 886,524 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F4 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 886,524 shares of the Issuer's common stock. The reporting person also holds options to acquire 444,653 shares of the Issuer's common stock, 236,023 of which are exercisable as of the date hereof. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 21:07 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 18,518 | $33.22 | $615,167.96 |
DisclosureSEC source: 0001104659-21-037933 · tm219986-1_4seq1.xml · nonDerivative · entry 2 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 886,624 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.69 to $33.67. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 21:07 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 11,382 | $34.06 | $387,670.92 |
DisclosureSEC source: 0001104659-21-037933 · tm219986-1_4seq1.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 905,142 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.68 to $34.67. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 17:58 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 11,380 | $35.84 | $407,859.20 |
DisclosureSEC source: 0001104659-21-025336 · tm217197-1_4seq1.xml · nonDerivative · entry 2 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 916,524 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.18 to $36.12. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 916,524 shares of the Issuer's common stock. The reporting person also holds options to acquire 444,653 shares of the Issuer's common stock, 229,189 of which are exercisable as of the date hereof. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 17:58 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 18,620 | $36.61 | $681,678.20 |
DisclosureSEC source: 0001104659-21-025336 · tm217197-1_4seq1.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 927,904 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.13 to $37.12. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 19, 2021 Filed Jan 19, 2021 21:47 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 7,157 | $42.38 | $303,313.66 |
DisclosureSEC source: 0001104659-21-005568 · tm213368-4_4seq1.xml · nonDerivative · entry 5 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 946,524 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.03 to $42.83. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F7 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 946,524 shares of the Issuer's common stock. The reporting person also holds options to acquire 444,653 shares of the Issuer's common stock, 224,438 of which are exercisable as of the date hereof. Read SEC document |
| January 19, 2021 Filed Jan 19, 2021 21:47 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 700 | $43.25 | $30,275.00 |
DisclosureSEC source: 0001104659-21-005568 · tm213368-4_4seq1.xml · nonDerivative · entry 4 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 953,681 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.86. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:47 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 12,396 | $43.07 | $533,895.72 |
DisclosureSEC source: 0001104659-21-005568 · tm213368-4_4seq1.xml · nonDerivative · entry 3 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 954,381 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.62 to $43.39. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:47 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 7,547 | $43.80 | $330,558.60 |
DisclosureSEC source: 0001104659-21-005568 · tm213368-4_4seq1.xml · nonDerivative · entry 2 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 966,777 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.42 to $44.41. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:47 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 2,200 | $45.01 | $99,022.00 |
DisclosureSEC source: 0001104659-21-005568 · tm213368-4_4seq1.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 974,324 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.75 to $45.50. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 1,000 | $41.97 | $41,970.00 |
DisclosureSEC source: 0001104659-20-134932 · tm2038101-3_4seq1.xml · nonDerivative · entry 5 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 976,524 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.28 to $41.65. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F7 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 976,524 shares of the Issuer's common stock. The reporting person also holds options to acquire 444,653 shares of the Issuer's common stock, 215,521 of which are exercisable as of the date hereof. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 13,750 | $43.10 | $592,625.00 |
DisclosureSEC source: 0001104659-20-134932 · tm2038101-3_4seq1.xml · nonDerivative · entry 4 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 977,524 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.37 to $42.48. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 7,058 | $43.90 | $309,846.20 |
DisclosureSEC source: 0001104659-20-134932 · tm2038101-3_4seq1.xml · nonDerivative · entry 3 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 991,274 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.37 to $43.39. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 7,492 | $44.83 | $335,866.36 |
DisclosureSEC source: 0001104659-20-134932 · tm2038101-3_4seq1.xml · nonDerivative · entry 2 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 998,332 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.38 to $44.40. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 700 | $45.82 | $32,074.00 |
DisclosureSEC source: 0001104659-20-134932 · tm2038101-3_4seq1.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,005,824 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.47 to $45.56. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 20:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 3,759 | $44.41 | $166,937.19 |
DisclosureSEC source: 0001104659-20-126992 · a4.xml · nonDerivative · entry 3 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,006,524 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.63 to $44.05. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F5 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 1,006,524 shares of the Issuer's common stock. The reporting person also holds options to acquire 444,653 shares of the Issuer's common stock, 208,687 of which are exercisable as of the date hereof. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 20:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 10,941 | $45.04 | $492,782.64 |
DisclosureSEC source: 0001104659-20-126992 · a4.xml · nonDerivative · entry 2 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,010,283 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.63 to $44.64. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 20:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 300 | $46.43 | $13,929.00 |
DisclosureSEC source: 0001104659-20-126992 · a4.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,021,224 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.73 to $46.09. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 16:25 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 1,529 | $24.83 | $37,965.07 |
DisclosureSEC source: 0001104659-20-106117 · a4.xml · nonDerivative · entry 3 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,021,524 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.70 to $25.00. F5 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 1,021,524 shares of the Issuer's common stock. The reporting person also holds options to acquire 444,653 shares of the Issuer's common stock, 195,019 of which are exercisable as of the date hereof. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 16:25 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 10,271 | $24.11 | $247,633.81 |
DisclosureSEC source: 0001104659-20-106117 · a4.xml · nonDerivative · entry 2 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,023,053 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.68 to $24.67. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 16:25 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 3,200 | $23.09 | $73,888.00 |
DisclosureSEC source: 0001104659-20-106117 · a4.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,033,324 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.60 to $23.57. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 17:15 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 5,964 | $23.19 | $138,305.16 |
DisclosureSEC source: 0001104659-20-096575 · a4.xml · nonDerivative · entry 2 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,036,524 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.07 to $23.27. F4 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 1,036,524 shares of the Issuer's common stock. The reporting person also holds options to acquire 444,653 shares of the Issuer's common stock, 188,185 of which are exercisable as of the date hereof. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 17:15 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 9,036 | $23.60 | $213,249.60 |
DisclosureSEC source: 0001104659-20-096575 · a4.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,042,488 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.29 to $24.28. Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 16:34 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 116,550 | $0.00 Strike: $9.78 | $0.00 |
DisclosureSEC source: 0001104659-20-042511 · a4.xml · derivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,550 Underlying: Common Stock · 116,550 shares Expires 2030-04-01 F1 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2021, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 21:16 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 11,250 | $17.00 | $191,250.00 |
DisclosureSEC source: 0001104659-19-061832 · a4.xml · nonDerivative · entry 2 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,051,524 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 1,051,524 shares of the Issuer's common stock. The reporting person also holds options to acquire 328,103 shares of the Issuer's common stock, 115,169 of which are exercisable as of the date hereof. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 21:16 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 11,250 | $17.02 | $191,475.00 |
DisclosureSEC source: 0001104659-19-061832 · a4.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,062,774 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 19:37 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 11,250 | $17.00 | $191,250.00 |
DisclosureSEC source: 0001104659-19-060674 · a4.xml · nonDerivative · entry 2 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,074,024 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 1,074,024 shares of the Issuer's common stock. The reporting person also holds options to acquire 328,103 shares of the Issuer's common stock, 115,169 of which are exercisable as of the date hereof. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 19:37 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 11,250 | $17.05 | $191,835.00 |
DisclosureSEC source: 0001104659-19-060674 · a4.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,085,274 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| October 31, 2019 Filed Nov 4, 2019 16:15 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 11,250 | $17.00 | $191,250.00 |
DisclosureSEC source: 0001104659-19-059505 · a4.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,096,524 F1 · kind: The sale reported on this Form 4 was made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Following the sale reported on this Form 4, the reporting person continues to beneficially own 1,096,524 shares of the Issuer's common stock. The reporting person also holds options to acquire 328,103 shares of the Issuer's common stock, 115,169 of which are exercisable as of the date hereof. Read SEC document |
| September 23, 2019 Filed Sep 25, 2019 16:31 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 11,250 | $17.05 | $191,812.50 |
DisclosureSEC source: 0001104659-19-051354 · a4.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,107,774 F1 · kind: The sale reported on this Form 4 was made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Following the sale reported on this Form 4, the reporting person continues to beneficially own 1,107,774 shares of the Issuer's common stock. The reporting person also holds options to acquire 328,103 shares of the Issuer's common stock, 106,870 of which are exercisable as of the date hereof. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.